Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Food labeling comments

This article was originally published in The Tan Sheet

Executive Summary

The agency is reopening the comment period for the notice of public hearing on the use of symbols to communicate nutrition information on food labels through Jan. 15, 2008, FDA announces in a Nov. 30 Federal Register notice. Comments were initially being accepted through Nov. 12. In September, FDA's Center for Food Safety and Applied Nutrition met with manufacturers and other industry stakeholders to discuss current food label nutrition programs being used on a voluntary basis. Industry has indicated it supports establishing a standard, but voluntary labeling system (1"The Tan Sheet" Sept. 17, 2007, p. 7)...

You may also be interested in...



Food Industry Hungry For Voluntary Use Of Nutrition Symbols Standard

Food manufacturers and other industry stakeholders support establishing a standard but voluntary labeling system that uses symbols to indicate the nutrition content of their products, industry representatives said during a public hearing sponsored by FDA's Center for Food Safety and Applied Nutrition Sept. 10-11

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel